Stephen Aselage
Director/Board Member at BIOCRYST PHARMACEUTICALS, INC.
Net worth: 321 762 $ as of 30/03/2024
Profile
Stephen J.
Aselage is an Independent Director at BioCryst Pharmaceuticals, Inc., and a Director at Patara Pharma LLC and Acuitas Therapeutics, Inc. He was the Chief Executive Officer & Director at Retrophin LLC, Chief Executive Officer at Kyalin Biosciences, Inc., and Chairman at Acer Therapeutics, Inc. He was also a Director at APT Pharmaceuticals, Inc., Opexa Therapeutics, Inc., Travere Therapeutics, Inc., and National Pku Alliance.
He worked as a Sales Manager at Genentech, Inc. and Rorer Pharmaceuticals, Inc. and was the Senior VP-North American Sales & Marketing at SangStat Medical Corp.
and Genzyme Corp.
He was the Executive VP-Global Commercial Operations at CTI BioPharma Corp.
and the Chief Business Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. He earned his undergraduate degree from the University of Notre Dame in 1973.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 12/06/2023 | 63,339 ( 0.03% ) | 321 762 $ | 30/03/2024 |
Stephen Aselage active positions
| Companies | Position | Start |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Director/Board Member | 03/01/2019 |
Patara Pharma LLC
 Patara Pharma LLC Pharmaceuticals: MajorHealth Technology Patara Pharma LLC provides biotechnology solutions. It develops biopharmaceutical therapy for the treatment of allergic and inflammatory diseases and conditions that affect orphan patient populations. The company was founded by William Gerhart, Pravin Soni and Ahmet Tutuncu in 2013 and is headquartered in San Diego, CA. | Director/Board Member | - |
Acuitas Therapeutics, Inc.
 Acuitas Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Acuitas Therapeutics is a private biotechnology company based in Vancouver, Canada that specializes in developing delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The Canadian company partners with pharmaceutical and biotechnology companies, academic institutes, and non-governmental organizations to advance nucleic acid therapeutics into clinical trials and the marketplace. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines, including Pfizer/BioNTech for Comirnaty®. The CEO of the company is Thomas Madden. | Director/Board Member | - |
Former positions of Stephen Aselage
| Companies | Position | End |
|---|---|---|
| ACER THERAPEUTICS INC. | Chairman | 16/11/2023 |
| TRAVERE THERAPEUTICS, INC. | Chief Executive Officer | 03/01/2019 |
Desert Gateway, Inc.
 Desert Gateway, Inc. Financial ConglomeratesFinance Desert Gateway, Inc. operates as a capital pool company. It is presently a development stage company seeking a potential acquisition of or merger with a yet to be identified business opportunity. The company was founded on February 8, 2008 and is headquartered in Bartlesville, OK. | Chairman | 20/02/2013 |
Retrophin LLC
 Retrophin LLC BiotechnologyHealth Technology Retrophin, Inc. provides biotechnology services. It is a biotechnology company dedicated to developing drugs for rare and life-threatening diseases. The company was founded in 2011 and is headquartered in New York, NY. | President | 20/02/2013 |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 31/08/2012 |
Training of Stephen Aselage
| University of Notre Dame | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| Private companies | 16 |
|---|---|
| Advanced Tissue Sciences, Inc. | Commercial Services |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| SangStat Medical Corp. | Health Technology |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
APT Pharmaceuticals, Inc.
 APT Pharmaceuticals, Inc. BiotechnologyHealth Technology APT Pharmaceuticals, Inc. operated as a drug development company. The company was founded on December 15, 1999 and was headquartered in Burlingame, CA. | Health Technology |
Patara Pharma LLC
Patara Pharma LLC Pharmaceuticals: MajorHealth Technology Patara Pharma LLC provides biotechnology solutions. It develops biopharmaceutical therapy for the treatment of allergic and inflammatory diseases and conditions that affect orphan patient populations. The company was founded by William Gerhart, Pravin Soni and Ahmet Tutuncu in 2013 and is headquartered in San Diego, CA. | Health Technology |
Acer Therapeutics, Inc. /Old/
 Acer Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. develops therapeutics for the treatment of orphan diseases. Its current pipeline consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD). The company was founded by Chris Schelling and is headquartered in Cambridge, MA. | Health Technology |
Desert Gateway, Inc.
Desert Gateway, Inc. Financial ConglomeratesFinance Desert Gateway, Inc. operates as a capital pool company. It is presently a development stage company seeking a potential acquisition of or merger with a yet to be identified business opportunity. The company was founded on February 8, 2008 and is headquartered in Bartlesville, OK. | Finance |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
| Rorer Pharmaceuticals, Inc. | |
Retrophin LLC
Retrophin LLC BiotechnologyHealth Technology Retrophin, Inc. provides biotechnology services. It is a biotechnology company dedicated to developing drugs for rare and life-threatening diseases. The company was founded in 2011 and is headquartered in New York, NY. | Health Technology |
Acuitas Therapeutics, Inc.
Acuitas Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Acuitas Therapeutics is a private biotechnology company based in Vancouver, Canada that specializes in developing delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The Canadian company partners with pharmaceutical and biotechnology companies, academic institutes, and non-governmental organizations to advance nucleic acid therapeutics into clinical trials and the marketplace. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines, including Pfizer/BioNTech for Comirnaty®. The CEO of the company is Thomas Madden. | Commercial Services |
Kyalin Biosciences, Inc.
 Kyalin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kyalin Biosciences, Inc. manufactures biopharmaceutical products. The firm develops an intranasal delivery form of carbetocin, which is a synthetic version of the natural occurring peptide hormone, oxytocin, for the treatment of core deficits that characterize the autistic spectrum disorders. The company was founded by Srinivas G. Rao and is headquartered in San Diego, CA. | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
| National Pku Alliance |
- Stock Market
- Insiders
- Stephen Aselage
